{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:55:09Z","timestamp":1793066109980,"version":"4.5.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This study aimed to investigate the characteristics and prognosis of recompensation in hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A total of 136 patients with HBV-related ACLF were followed up until the end of the study. Patients were categorized into recompensation and non-recompensation groups based on whether recompensation occurred in the first year. The survival rate and incidence of recompensation were calculated using the Kaplan\u2013Meier method.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>According to the BAVENO VII consensus criteria, 56 (41.18%) of these patients with ACLF regained recompensation in the 1-year follow-up. The recompensated group had less severe liver damage, higher alpha-fetoprotein, lower age, and lower model for end-stage liver disease score. Specifically, in terms of complications, the recompensated group showed a lower incidence compared with the non-recompensated group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.05). The 3-, 6-, 12-, 36-, and 60-month cumulative survival rates of ACLF were 44.9, 43.4, 43.4, 40.4, and 40.4% respectively. Among the patients who survived beyond 90 days, 57\/61 (93.44%) patients showed recompensation of ACLF (with one patient recovering to recompensation after more than 1 year of follow-up), the 3-, 6-, 12-, and 24-month cumulative recompensation rates were 56.5, 90.9, 94.6, and 97.3%, respectively. Among the 57 patients with recompensation of ACLF, 87.7% maintained a stable condition, and 10.5% were diagnosed with hepatocellular carcinoma (HCC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Milder necrosis, less inflammation, and more vigorous hepatic regeneration are conducive to recompensation and a better long-term prognosis in ACLF. However, the occurrence of HCC cannot be avoided and regular monitoring is necessary in the recompensation of ACLF.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/meg.0000000000002891","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T17:03:30Z","timestamp":1732640610000},"page":"337-342","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Recompensation features and prognosis in hepatitis B virus-related acute-on-chronic liver failure patients"],"prefix":"10.1097","volume":"37","author":[{"given":"Junchao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Xiamen Hospital of Traditional Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Infection, the First Affiliated Hospital of Xiamen University, Xiamen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Hepatology Research Institute, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"R1-20250207","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/17474124.2017.1361822","article-title":"Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.","volume":"11","author":"Okada","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R2-20250207","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.cgh.2018.04.063","article-title":"Effects of virologic response to treatment on short- and long-term outcomes of patients with chronic hepatitis b virus infection and decompensated cirrhosis.","volume":"16","author":"Jang","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R3-20250207","first-page":"915","article-title":"Reversal of cirrhotic decompensation: recompensation.","volume":"27","author":"He","year":"2019","journal-title":"Chin J Hepatol"},{"key":"R4-20250207","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII \u2013 renewing consensus in portal hypertension.","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"R5-20250207","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jhep.2022.07.037","article-title":"Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis.","volume":"77","author":"Wang","year":"2022","journal-title":"J Hepatol"},{"key":"R6-20250207","doi-asserted-by":"crossref","first-page":"e2304381","DOI":"10.1002\/advs.202304381","article-title":"The 90-day survival threshold: a pivotal determinant of long-term prognosis in HBV-ACLF patients \u2013 insights from a prospective longitudinal cohort study.","volume":"11","author":"Xiao","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"R7-20250207","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/MCG.0000000000000987","article-title":"Long-term prognosis of acute-on-chronic liver failure survivors.","volume":"53","author":"Yoon","year":"2019","journal-title":"J Clin Gastroenterol"},{"key":"R8-20250207","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/liv.14072","article-title":"Long-term outcomes of patients with hepatitis B virus-related acute on chronic liver failure: an observational cohort study.","volume":"39","author":"Lin","year":"2019","journal-title":"Liver Int"},{"key":"R9-20250207","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s12072-019-09946-3","article-title":"Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update.","volume":"13","author":"Sarin","year":"2019","journal-title":"Hepatol Int"},{"key":"R10-20250207","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jama.2023.5997","article-title":"Diagnosis and management of cirrhosis and its complications: a review.","volume":"329","author":"Tapper","year":"2023","journal-title":"JAMA"},{"key":"R11-20250207","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL clinical practice guidelines for the management of patients with decompensated cirrhosis.","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"R12-20250207","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12876-022-02239-4","article-title":"Long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure: a retrospective study.","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"R13-20250207","first-page":"505","article-title":"Lamivudine, interferon-alpha and oxymatrine treatment for the surviving hepatic failure patients with hepatitis B.","volume":"17","author":"Chen","year":"2009","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"R14-20250207","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/jvh.13732","article-title":"Reversibility of acute-on-chronic liver failure syndrome in hepatitis B virus-infected patients with and without prior decompensation.","volume":"29","author":"Wang","year":"2022","journal-title":"J Viral Hepat"},{"key":"R15-20250207","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11684-020-0790-9","article-title":"The \u2018Traditional Chinese medicine regulating liver regeneration\u2019 treatment plan for reducing mortality of patients with hepatitis B-related liver failure based on real-world clinical data.","volume":"15","author":"Dai","year":"2021","journal-title":"Front Med"},{"key":"R16-20250207","first-page":"65","article-title":"Characterization of the clinical features in HBV-related acute-on-chronic liver failure.","volume":"28","author":"Yuan","year":"2022","journal-title":"Altern Ther Health Med"},{"key":"R17-20250207","doi-asserted-by":"crossref","first-page":"5062873","DOI":"10.1155\/2020\/5062873","article-title":"Value of liver regeneration in predicting short-term prognosis for patients with hepatitis b-related acute-on-chronic liver failure.","volume":"2020","author":"Wang","year":"2020","journal-title":"Biomed Res Int"},{"key":"R18-20250207","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s12876-021-02054-3","article-title":"Development and validation of the nomogram based on INR and eGFR for estimation of mortality in patients with acute-on-chronic hepatitis B liver failure.","volume":"21","author":"Li","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"R19-20250207","doi-asserted-by":"crossref","first-page":"16462.doi","DOI":"10.1038\/s41598-019-53029-0","article-title":"Artificial liver support system therapy in acute-on-chronic hepatitis B liver failure: Classification and regression tree analysis.","volume":"9","author":"Huang","year":"2019","journal-title":"Sci Rep"},{"key":"R20-20250207","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00063-017-0282-0","article-title":"Akutes Leberversagen [Acute liver failure].","volume":"112","author":"Koch","year":"2017","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"R21-20250207","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/7628763","article-title":"Alpha-fetoprotein as a predictive marker for patients with hepatitis b-related acute-on-chronic liver failure.","volume":"2018","author":"Wang","year":"2018","journal-title":"Can J Gastroenterol Hepatol"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T18:02:31Z","timestamp":1738951351000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000002891","relation":{},"ISSN":["1473-5687"],"issn-type":[{"value":"1473-5687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,14]]}}}